THANK YOU FOR SUBSCRIBING
The company has been creating a proprietary technology to develop a new range of ultra-potent IO therapies that can be activated secretly within the tumor
Fremont, CA: Tumor selective immuno-oncology (IO) therapy provider Xiilo Therapeutics secured USD 100.5 million in its Series B round of financing led by Takeda Ventures, Inc. The round was also participated by new investors SV Health Investors, MRL Ventures Fund, RiverVest Venture Partners, Bay City Capital, Solasta Ventures, M Ventures, and Ipsen Ventures along with existing investors F-Prime Capital and Atlas Venture. Proceeds from this round will be used to progress Xilio's first two therapeutic candidates, XTX201 (tumor-selective IL-2) and XTX101 (tumor-selective aCTLA4 mAb) through Investigational New Drug (IND) enabling studies and into Phase 1 clinical trials, along with advance additional tumor-selective cytokine programs using Xilio's proprietary technology.
"We are fortunate to have the support of investors who share our vision to deliver highly potent and effective tumor-selective cancer therapies to patients," said Rene Russo, Chief Executive Officer of Xilio Therapeutics. "This is a transformational moment for the company as we work to bring our first development programs to patients with cancer and expand our tumor-selective cytokine pipeline."
Stay ahead of the industry with exclusive feature stories on the top companies, expert insights and the latest news delivered straight to your inbox. Subscribe today.
[vendor_logo_first]The company has been creating a proprietary technology to develop a new range of ultra-potent IO therapies that can be activated secretly within the tumor. These tumor-selective therapies are designed to overcome the significant toxicities associated with validated IO therapies, like IL-2 and aCTLA4, which, as history speaks, has limited the number of patients that can be treated while also preventing patients from completing full courses of treatment. Meanwhile, XTX201 (IL-2) and XTX101 (aCTLA4 mAb) have demonstrated tumor-selective activity in preclinical models, significantly widening the potential therapeutic index for these therapies.
"IO has emerged as a major driver of cancer therapeutic development, and agents in this space have proven effective, resulting in compelling durable clinical responses," said Jayson Punwani, Investment Partner with Takeda Ventures. "We believe Xilio's proprietary platform offers a compelling approach that builds upon the advancements in IO therapeutics. It is encouraging to see such a strong and supportive Series B syndicate, including leading venture capital groups and strategic partners. We look forward to working with Xilio's current investors and the leadership team to support the advancement of its pipeline into the clinic." As part of the deal, Mr. Punwani, Mike Ross of SV Health Investors, Peter Dudek of MRL Ventures Fund, and Nancy Hong of RiverVest Venture Partners will join the Board of Directors of Xilio.
See Also : Top Healthcare Analytics Companies
More in News